85277-86-7Relevant academic research and scientific papers
NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
-
Page/Page column 98, (2015/06/25)
The invention relates to novel arylalkenylpropargylamine derivatives of general formula (I) or enantiomers or diastereomers thereof or salts, optionally pharmaceutically acceptable salts, or solvates of any of these. The compounds can be used in treating or preventing a disease or condition in a mammal related to monoamine oxidase dysfunction, especially in neurodegenerative diseases, e.g. Parkinson's disease, Alzheimer's disease or Huntington's disease.
Enzyme-activated irreversible inhibitors of monoamine oxidase: Phenylallylamine structure-activity relationships
McDonald,Lacoste,Bey,Palfreyman,Zreika
, p. 186 - 193 (2007/10/02)
Seventeen 2-aryl-3-haloallylamine derivatives were prepared and evaluated as inhibitors of monoamine oxidase (MAO, EC 1.4.3.4). The synthesis of these compounds was achieved from either α-methylstyrene or ring-substituted phenylacetic acid derivatives. Wi
Allyl amine MAO inhibitors
-
, (2008/06/13)
Compounds of the formula STR1 wherein: R is phenyl, phenyl monosubstituted, disubstituted, or trisubstituted by (C1 -C8) alkyl, (C1 -C8)alkoxy, hydroxy, chlorine, bromine, iodine, fluorine, trifluoromethyl, nitr
